TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05260216

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive prevention and treatment
Description: Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Comprehensive prevention and treatment
Description: Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Routine prevention
Description: Routine prevention includes fluoride foam application twice a year and oral hygiene guidance.
Study: NCT00240825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT05590962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR Nudge
Description: Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥1 for Stage IV cancer patients and ≥2 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
Study: NCT05501327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLI-F06
Description: Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLI-F06
Description: Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLI-F06
Description: Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
Study: NCT04520139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl-Cysteine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl-Cysteine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study: NCT04861116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention program for test anxiety
Description: 12-week ICT-based manualized, targeted and facilitated individual intervention for adolescent students, that aims to promote compassion, acceptance and mindfulness, in order to help improve test anxiety's regulation (and consequently symptom reduction), as well as increase general and school-related well-being, while promoting valued life action.
Study: NCT06190756

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular and Baroreflex stimulation by Tilting
Description: Tilt of the patient at 4 angles (22°, 42°, 58° and 80°), the order is randomized for 3 angles (22°, 42°, 58°) while 80° will always be last.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular and Baroreflex stimulation by Tilting
Description: Tilt of the patient at 4 angles (22°, 42°, 58° and 80°), the order is randomized for 3 angles (22°, 42°, 58°) while 80° will always be last.

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular and Baroreflex stimulation by Lower Body Negative Pressure
Description: The patient will undergo 4 level of LBNP (10Torr, 20Torr, 35Torr, 50Torr), the order is randomized for 3 intensities (10Torr, 20Torr, 35Torr) while 50Torr will always be last.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular and Baroreflex stimulation by Lower Body Negative Pressure
Description: The patient will undergo 4 level of LBNP (10Torr, 20Torr, 35Torr, 50Torr), the order is randomized for 3 intensities (10Torr, 20Torr, 35Torr) while 50Torr will always be last.
Study: NCT06511362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional stabilization training
Description: At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perturbation exercises
Description: At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
Study: NCT05839184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic toy
Description: Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
Study: NCT04907500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens
Description: Cataract surgery
Study: NCT05117385

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract
Description: 1 capsule per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract
Description: 1 capsule per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Botanical extract
Description: 1 capsule per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract
Description: 1 capsule per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract
Description: 1 capsule per day
Study: NCT04615910

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT
Study: NCT05253911

Intervention type: DRUG
Intervention: TUKYSA®
Description: tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.

Intervention type: DRUG
Intervention: TUKYSA®
Description: tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.
Study: NCT06129045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-time educational video
Description: Sleep hygiene educational tips provided through a video participants watch on their own.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video plus repeated education
Description: Sleep hygiene educational tips are provided first through a video participants watch on their own and then tips are repeated through daily automated text messaging for an additional 4 weeks.
Study: NCT06646770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Description: Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lobectomy
Description: Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.
Study: NCT06584825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced Vitals Monitoring
Description: For participants in the intervention group, they will receive the enhanced continuous vital sign monitoring, on top of the standard of care monitoring as prescribed per the care team. The enhanced monitoring will be provided during the entire time period of hospitalization (up to 30 days after surgery), using the Philips monitor (i.e. heart rate and oxygen saturation continuously and blood pressure once an hour while awake). Participants and caregivers will be educated how to put on and off the devices by the study coordinator.~When participants return home, they will perform thrice-daily monitoring using the Cloud DX Inc. Home kit and daily questionnaires at home 7 days after discharge (or 30 days after surgery, whichever occurs first).
Study: NCT02269683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted distal pancreatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic distal pancreatectomy
Study: NCT06086119

Intervention type: DIAGNOSTIC_TEST
Intervention: to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.
Description: Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
Study: NCT05157568

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Streaming (ES)
Description: Participants will complete 8 weeks (1 class per week) of supervised exercise online. No equipment is required. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Streaming + Equipment (ES+E)
Description: Participants will complete 8 weeks (1 class per week) of supervised exercise online. Each participant will have a stationary exercise bike delivered to their home for use during their live classes. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will complete 8 weeks (1 class per week) of in-person supervised exercise.
Study: NCT05404126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: • Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: • Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
Study: NCT05904756

Intervention type: DEVICE
Intervention: framework for implant supported prosthesis, fabricated from metal of polyetherketoneketone
Description: evaluation of patient satisfaction and oral healty related quality of life

Intervention type: DEVICE
Intervention: framework for implant supported prosthesis, fabricated from metal of polyetherketoneketone
Description: evaluation of patient satisfaction and oral healty related quality of life
Study: NCT05984693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Assisted Instruction
Description: Video Assisted Instruction
Study: NCT06498089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: This drug will be used in both arms. Patients' initial daily prednisone dose will be calculated according to their weights (0.6mg \* weight(kg), maximum 50mg/day), and then tapered gradually during the study course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: This drug will be used in both arms. Patients' initial daily prednisone dose will be calculated according to their weights (0.6mg \* weight(kg), maximum 50mg/day), and then tapered gradually during the study course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: This drug will be used in the traditional arm. A dose of 15mg per week will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: This drug will be used in the traditional arm. A dose of 15mg per week will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: This drug will be used in the precise treatment arm. For patients in constitutional type a dose (8mg/kg weight) will be used every 2 weeks (iv drip) for 12 weeks, then a dose (8mg/kg weight) will be used every 4 weeks (iv drip). For patients in vascular inflammation type, a dose (8mg/kg weight) will be used every 4 weeks (iv drip).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: This drug will be used in the precise treatment arm. A sustained release tablet will be used (11mg per day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: This drug will be used in the precise treatment arm. A dose of 40mg (ih) will used every 2 weeks.
Study: NCT06648980

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytoglycogen
Description: Phytoglycogen; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
Study: NCT05117398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin administration
Description: A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic therapy
Description: Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
Study: NCT06671587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine/lixisenatide)
Description: iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~- iGlarLixi must not be mixed with other insulins nor diluted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gla-100 (insulin glargine)
Description: Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
Study: NCT06671938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exidavnemab
Description: The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The trial medication will be administered as an intravenous (IV) infusion
Study: NCT06618521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypertensive drug (Methyldopa 250 mg)
Description: Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive drug (Methyldopa 250 mg)
Description: Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive drug (Methyldopa 250 mg)
Description: Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: Each women in the second group will receive Mat Pilates training exercise for 40 minutes/ day, 3 days/week, for 12 weeks beginning 20 weeks' gestation. The Pilates exercise includes pelvic floor exercise, deep tummy strengthening, pelvic tilt, upper back stretch, the cat stretch, thigh stretch, the sword, sword arm, and wagging the tail.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit exercise training
Description: Each women in group C will receive circuit training exercises in form of single leg curl up and press, sumo squat and row to reverse fly stand for 40 minutes/ day, 3 days/ week, for 12 weeks beginning 20 weeks' gestation. The Circuit exercise training includes sumo squat, quadruped extension, row to reverse fly stand, and single leg curls up.
Study: NCT06622291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo group. The standard CPB protocol involves delivering an air-gas mixture to the cardiopulmonary bypass circuit during cardiac surgery and avoiding the use of nitric oxide within 12 hours after surgery.
Study: NCT06623877

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: renal shear wave elastography
Description: Renal shear wave elastography is a non-invasive ultrasound elastography technique that allows measurements of tissue stiffness. It provides real-time measurements of shear wave velocity (SWV) generated with an acoustic impulse, thereby providing quantitative information about tissue elasticity. Harder tissues have been shown to have higher SWV .~Renal shear wave elastography will be done to both groups

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: renal shear wave elastography
Description: Renal shear wave elastography is a non-invasive ultrasound elastography technique that allows measurements of tissue stiffness. It provides real-time measurements of shear wave velocity (SWV) generated with an acoustic impulse, thereby providing quantitative information about tissue elasticity. Harder tissues have been shown to have higher SWV .~Renal shear wave elastography will be done to both groups
Study: NCT06695247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Patients will be recommended to exercise 3 days/week, 20 minutes per session, for 12 weeks using personalized intervention determined by a consultation with a clinical exercise physiologist (CEP)
Study: NCT06718270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells Infusion
Description: chimeric antigen receptor T cells
Study: NCT05873335

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mixtures of nitrogen, air, and carbon dioxide
Description: Hypoxia was induced to different and stable levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, air, and carbon dioxide controlled by the study physician by adjusting gas flows with valves according to breath-by-breath estimates of oxygen saturation calculated from end-tidal PO2 and PCO2 displayed on a screen using LabVIEW 2015
Study: NCT06730516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost (Xalatan)
Description: latanoprost 0.005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2 %
Description: Brimonidine0.2
Study: NCT06730100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pH Low Insertion Peptide-exatecan Conjugate CBX-12
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-rays
Study: NCT06731738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteric acid
Description: A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteric acid
Description: A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteric acid
Description: A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium injection
Description: Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium injection
Description: Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium injection
Description: Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.
Study: NCT06730763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (TDCS) is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: selected traditional physical therapy program for improve balance and decrease risk of falling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: selected traditional physical therapy program for improve balance and decrease risk of falling